CompletedPhase 3NCT01728805
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
Studying Aggressive primary cutaneous T-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Kyowa Kirin, Inc.
- Principal Investigator
- Dmitri O. Grebennik, MDKyowa Kirin, Inc.
- Intervention
- KW-0761(biological)
- Enrollment
- 372 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2012 – 2021
Study locations (30)
- University of Alabama - Birmingham, Birmingham, Alabama, United States
- Banner MD Anderson, Gilbert, Arizona, United States
- City of Hope National Medical Center, Duarte, California, United States
- UCLA Medical Center, Los Angeles, California, United States
- Stanford Medical Center, Stanford, California, United States
- University of Colorado, Aurora, Colorado, United States
- Yale University School of Medicine - Yale Cancer Center, New Haven, Connecticut, United States
- H. Lee Moffitt Cancer Center, Tampa, Florida, United States
- The Winship Cancer Institute (Emory University), Atlanta, Georgia, United States
- Northwestern University, Chicago, Illinois, United States
- Indiana University, Indianapolis, Indiana, United States
- University of Kansas Cancer Center, Westwood, Kansas, United States
- Tulane University Medical Center, New Orleans, Louisiana, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Boston Medical Center, Department of Medicine, Section of Hem/Onc, Boston, Massachusetts, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01728805 on ClinicalTrials.govOther trials for Aggressive primary cutaneous T-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05544968Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic MalignanciesMedical College of Wisconsin
- RECRUITINGPHASE1NCT07055477A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)National Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07047885Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)H. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGNANCT06860880Combating Cancer-Related Fatigue: A Personalized Supportive Care ProgramUNC Lineberger Comprehensive Cancer Center
- RECRUITINGPHASE1, PHASE2NCT07022964CD5 CAR T-Cell Therapy for r/r T-cell LymphomasBeijing GoBroad Hospital
- RECRUITINGNCT07132567Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result SurveillanceKyowa Kirin Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT06925464CD7 CAR T-Cell Therapy for r/r T-cell LymphomasBeijing GoBroad Hospital
- RECRUITINGPHASE1NCT06914037A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological MalignanciesTianjin Medical University Cancer Institute and Hospital
See all trials for Aggressive primary cutaneous T-cell lymphoma →